Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy could ease daily steroid dependence for rare hormone disorder

NCT ID NCT04783181

First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 15 times

Summary

This study tests a new gene therapy for adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production and requires lifelong steroid medication. The treatment uses a harmless virus to deliver a working copy of the faulty gene, aiming to reduce abnormal hormone levels and potentially lower the need for daily steroids. Eight adults are enrolled in this early-phase trial to check safety and find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Lucas Research, Inc.

    Morehead City, North Carolina, 28557, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892-1932, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.